BRANDI OLIVER: Open Payments
NPI 1912751793 · EASTON, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$987 in 42 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $864 · 2025 $987
Food & beverage: $987
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $198 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 8 | $152 |
| GENZYME CORPORATION | 4 | $125 |
| ABBVIE INC. | 5 | $109 |
| QOL Medical, LLC | 3 | $97 |
| Intercept Pharmaceuticals, Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Celltrion USA Inc. | 3 | $56 |
| Madrigal Pharmaceuticals | 2 | $35 |
| Novo Nordisk Inc | 1 | $34 |
Products named: TREMFYA, XIFAXAN, DUPIXENT, Sucraid, OCALIVA, VEGZELMA, ENTYVIO, CREON.
Industry payments across MD — which companies pay providers there.
